Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06784193 · readout in 284 d
Sponsored by Olema Pharmaceuticals, Inc. (industry) · OLMA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
180estimated
Sites
8
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-16 | actual | When the study began enrolling |
| Primary completion | 2027-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
- Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Metastatic Breast Cancer
- Fulvestrant
- Palazestrant
Interventions
- Drug: OP-3136
- Drug: Fulvestrant
- Drug: Palazestrant
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicities in the Dose Escalation Arms
measured Up to 28 days
Incidence of adverse events and laboratory abnormalities
measured Up to 26 months
Permalink · OLMA's whole pipeline · Catalyst calendar · Every registered study · What changed